{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental', 'health, and general health. The questionnaire contains 36 questions within these domains', 'that ask the participant to recall how they felt during the past seven days.', '9.6.4.', 'Health Status (EQ-5D-5L & EQ-VAS)', 'EQ-5D-5L consists of 2 concepts - the EQ-5D-5L descriptive system and the EQ-VAS.', 'The EQ-5D-5L is a self-reported descriptive system of health-related quality of life states', 'consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort,', 'anxiety/depression) each of which can take one of five responses. The responses record', 'five levels of severity (no problems/slight problems/moderate problems/severe', 'problems/extreme problems) within a particular EQ-5D dimension. Self-reported health', \"status captured by EQ-5D-5L relates to the participant's situation at the time of\", 'completion.', \"The EQ VAS records the respondent's self-rated health on a vertical, visual analogue\", 'scale where the endpoints are labeled \"the best health you can imagine\\' and \"the worst', \"health you can imagine' at the time of completion. This information is used as a\", 'quantitative measure of health outcome as judged by individual participants.', '9.6.5.', 'Work Productivity and Activity Impairment (WPAI-ANS-CPV)', 'The WPAI-ANS-CPV is an anemia specific questionnaire designed as a self-reported', 'quantitative assessment of social functioning related to work and regular daily activities.', 'It contains two main concepts- work productivity impairment measured via absenteeism', '(time missed from work), presenteeism (impairment at work) and regular daily activity', 'impairment. The questionnaire contains 6 questions and asks the patient to recall work', 'and activity impairment over the past 7 days.', '9.7.', 'Actigraphy', 'Patients with anemia in CKD can experience decreased physical functioning and sleep', 'disturbances [KDIGO, 2012]. Therefore, actigraphy assessment in this study will be', 'conducted as a means to measure changes in the physical activity and sleep from a', 'baseline measurement taken prior to Randomization (Day 1) to the end of study. The data', 'collected may be used to conduct exploratory analyses of physical activity and sleep.', 'ActiGraph GT9X Link is being piloted in this study to capture and record high resolution', 'human activity information by using a validated solid state 3-axis MEMS accelerometer', 'and proprietary filtering algorithm to report daily movement associated with physical', 'activity and sleep. This device will capture patterns of activity throughout the day and', 'night.', 'Physical activity will be measured by subject activity metrics such as steps taken,', 'physical activity intensity, and activity/sedentary bouts.', 'Sleep activity will be measured by subject sleep period metrics such as total sleep time,', 'sleep latency and sleep efficiency.', '64']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Prior to the participant leaving the study site at the screening visit, the participant must', 'have been trained on how to position the device to their arm, how to charge the battery', 'and check the battery status. These topics are all covered in the Participant Information', 'Leaflet and further instructions regarding distribution, operation, retrieval of ActiGraph', 'GT9X Link devices will be provided in the SRM.', 'All efforts should be made to encourage participation in this activity monitoring', 'assessment. If a participant is unable to take part, the reason should be documented, and', 'they may continue in the study.', 'The technical performance of the Actigraph device will also be closely monitored and', 'assessed during the study and the Sponsor may elect to discontinue this assessment if', 'device related difficulties are encountered.', '9.8.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.9.', 'Genetics', 'A 6 mL blood sample for DNA isolation will be collected from participants who have', 'consented to participate in the genetics analysis component of the study. Participation is', 'optional. Participants who do not wish to participate in the genetic research may still', 'participate in the study.', 'In the event of DNA extraction failure, a replacement genetic blood sample may be', 'requested from the participant. Signed informed consent will be required to obtain a', 'replacement sample unless it was included in the original consent.', 'See Section 12.5 (Appendix 5) for Information regarding genetic research. Details on', 'processes for collection and shipment and destruction of these samples can be found in', 'Q2 Solutions Investigator Manual', '9.10.', 'Storage Biomarkers', 'Blood samples will not be stored for biomarker analysis in this study', '9.11.', 'Healthcare Resource Utilization and Economics', 'Healthcare resource utilization and health economic data, associated with medical', 'encounters, will be collected in the CRF by the investigator and study-site personnel for', 'all participants throughout the study. Protocol-mandated procedures, tests, and encounters', 'are excluded.', 'The data collected may be used to conduct exploratory economic analyses and will', 'include:', 'Number and duration of medical care encounters, including surgeries, and other', 'selected procedures (inpatient and outpatient)', '65']\n\n###\n\n", "completion": "END"}